Omeros (NASDAQ:OMER) Shares Up 8.1% – Should You Buy?

Omeros Corporation (NASDAQ:OMER) shares rose 8.1% on Monday . The stock traded as high as $8.49 and last traded at $8.5090. Approximately 1,138,047 shares traded hands during trading, a decline of 30% from the average daily volume of 1,620,168 shares. The stock had previously closed at $7.87.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on OMER. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. D. Boral Capital reissued a “buy” rating and set a $36.00 price objective on shares of Omeros in a report on Friday, November 14th. Wall Street Zen downgraded Omeros from a “hold” rating to a “sell” rating in a research report on Saturday. WBB Securities reiterated a “strong-buy” rating and set a $45.00 target price on shares of Omeros in a research note on Wednesday, October 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Omeros presently has an average rating of “Moderate Buy” and a consensus target price of $33.67.

Omeros Stock Performance

The stock has a market capitalization of $607.61 million, a P/E ratio of -4.06 and a beta of 2.39. The firm’s 50-day simple moving average is $5.97 and its 200 day simple moving average is $4.58.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.39. As a group, research analysts expect that Omeros Corporation will post -3.09 earnings per share for the current fiscal year.

Institutional Trading of Omeros

Several institutional investors and hedge funds have recently bought and sold shares of the business. Harbour Investments Inc. boosted its stake in shares of Omeros by 51.9% during the 1st quarter. Harbour Investments Inc. now owns 9,218 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 3,149 shares during the period. Russell Investments Group Ltd. lifted its holdings in Omeros by 113.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 5,677 shares during the last quarter. Trexquant Investment LP bought a new position in Omeros during the first quarter worth $88,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of Omeros in the second quarter valued at $32,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Omeros by 829.6% in the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 11,971 shares during the period. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.